Biomarker: C073-IgE Insulin, Human

Overview

This biomarker measures immunoglobulin E (IgE) antibodies directed against human insulin in serum. Insulin-specific IgE is associated with immediate, type I hypersensitivity reactions, which may cause injection-site itching, urticaria, angioedema, respiratory symptoms, hypotension, or anaphylaxis. Elevated levels may support sensitization to insulin, while a negative result makes IgE-mediated insulin allergy less likely. Clinical interpretation requires correlation with the timing and features of symptoms because insulin-specific IgE can occur without clinically relevant allergy and may not reliably distinguish sensitization from true allergy.

Clinical Use Cases

Evaluation of suspected immediate hypersensitivity reactions to recombinant or biosynthetic human insulin.
Support for the diagnostic work-up of localized or systemic reactions occurring soon after insulin administration.
Assessment of sensitization to human insulin alongside clinical history and, when appropriate, skin-prick or intradermal testing.
Investigation of possible cross-reactivity among human, porcine, and bovine insulin preparations.
Selection of potentially tolerated insulin preparations in patients with suspected insulin allergy.
Monitoring or research assessment during insulin-allergy management or desensitization, although the test should not be used as the sole measure of clinical response.

Specimen Types

Venous blood serum.
Plasma may be accepted by some immunoassay platforms, but serum is the usual specimen for clinical testing.

Measurement Methods

In-vitro allergen-specific IgE immunoassay, commonly a solid-phase fluorescent enzyme immunoassay such as ImmunoCAP.
Skin-prick testing with insulin preparations.
Intradermal or intracutaneous testing with selected insulin preparations.
Basophil activation or histamine-release assays in specialized clinical or research settings.
Results are commonly reported in kUA/L or kIU/L, with assay-specific reference ranges and interpretive thresholds. One clinical study considered values above 0.35 kIU/L positive, but thresholds are not universally interchangeable across methods.

Test Preparation and Influencing Factors

No special preparation or fasting is generally required for blood collection.
The specimen is usually collected as serum from venous blood and processed according to the testing laboratory’s requirements.
Recent or ongoing exposure to insulin may influence antibody detection and should be documented, including the insulin product, formulation, dose, route, and timing of administration.
Reactions to excipients or additives, such as protamine, preservatives, or other formulation components, may mimic or accompany insulin allergy; testing may therefore need to include relevant products or additives.
Antihistamines generally do not alter serum-specific IgE measurement, but they may suppress skin-test responses. Medication instructions for skin testing differ from those for blood testing.
Total IgE, atopic disease, diabetes treatment history, and prior insulin exposure may affect interpretation.
A positive result indicates sensitization and does not by itself establish clinically significant allergy. Results should be interpreted with symptom timing, physical findings, and other allergy testing.